US delay for GSK/Valeant's novel antiepileptic Potiga
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Valeant Pharmaceuticals have hit a three-month delay in achieving US approval for their novel antiepileptic Potiga (ezogabine).